EGFR and neoplasm: An evaluation of subcutaneous tumor control by A97L–T cells in the presence of full IgG versus F(ab′)2 fragments of cetuximab or avelumab revealed a role for the Fc tail in tumor control when targeting EGFR but not PD-L1 (Supplemental Figure 9, A and B).